CompletedNot Applicable

SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors

Slovenia65 participantsStarted 2019-01-01

Plain-language summary

This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors. The study focuses on systematic monitoring and optimization of the SBRT treatment process, including adherence to the implemented protocol, with the aim of simplifying methods while maintaining treatment safety.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Patients with liver tumors, liver metastases, or pancreatic tumors eligible for stereotactic body radiotherapy (SBRT) * Planned treatment with SBRT according to institutional protocol * Ability to comply with treatment and follow-up procedures * Signed informed consent Exclusion Criteria: * Contraindications for SBRT according to institutional radiotherapy protocol * Prior radiotherapy that prevents safe SBRT delivery to the target region * Severe uncontrolled comorbidities preventing safe SBRT treatment * Pregnancy * Inability to provide informed consent or comply with study procedures

What they're measuring

Treatment Safety (Radiotherapy-Related Toxicity)

Timeframe: From start of SBRT up to 12 months after treatment

Trial details

NCT IDNCT07407257

SponsorInstitute of Oncology Ljubljana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Liver Neoplasms trials